Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bristol-Myers Squibb
Adjuvant treatment for node-positive breast cancer approved in Europe
April 17th, 2005
Bristol-Myers Squibb announces the approval of Taxol (paclitaxel) for the treatment of early stage node-positive breast cancer following standard anthracycline and cyclophosphamide (AC) therapy. According to the approval, adjuvant treatment with Taxol should be regarded as an alternative to extended AC therapy. Through the mutual recognition procedure initiated via the Medicines Evaluation Board in the Netherlands, this new indication applies to 15 European Union member states. Taxol is already approved in the adjuvant setting in the U.S. and Switzerland. The recommended dose of Taxol for node-positive breast cancer is the already approved single...
Source: Women's Health Law Weekly (2005-04-17)
|
